- Home
- ITCI
as 12-26-2024 12:38pm EST
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 8.0B | IPO Year: | N/A |
| Target Price: | $97.67 | AVG Volume (30 days): | 464.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.86 | EPS Growth: | N/A |
| 52 Week Low/High: | $62.78 - $93.45 | Next Earning Date: | 10-30-2024 |
| Revenue: | $613,728,000 | Revenue Growth: | 46.08% |
| Revenue Growth (this year): | 48.41% | Revenue Growth (next year): | 38.26% |
Stock Insider Trading Activity of Intra-Cellular Therapies Inc. (ITCI)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Mates Sharon | ITCI | Chairman and CEO | Dec 4 '24 | Sell | $85.10 | 102,697 | $8,722,500.92 | 1,093,662 | |
| Halstead Michael | ITCI | President | Nov 12 '24 | Sell | $89.27 | 41,583 | $3,692,100.03 | 7,764 |
Latest Intra-Cellular Therapies Inc. News
ITCI Breaking Stock News: Dive into ITCI Ticker-Specific Updates for Smart Investing
GlobeNewswire
15 days ago
Intra-Cellular Therapies Presents Data from the CAPLYTA Adjunctive MDD Phase 3 Program at the American College of Neuropsychopharmacology Annual Meeting
Zacks
22 days ago
ITCI Submits sNDA to the FDA for Expanded Use of Caplyta in MDD
MT Newswires
23 days ago
Intra-Cellular Therapies Files Supplemental NDA for Caplyta as Adjunctive Treatment for Major Depressive Disorder
GlobeNewswire
23 days ago
Intra-Cellular Therapies Submits Supplemental New Drug Application (sNDA) to FDA for CAPLYTA® (lumateperone) for the Treatment of Major Depressive Disorder as Adjunctive Therapy
Zacks
a month ago
Why Is Intra-Cellular (ITCI) Up 2.2% Since Last Earnings Report?
BioPharma Dive
a month ago
How Intra-Cellular surprised Wall Street by breaking character
MT Newswires
a month ago
UBS Raises Price Target on Intra-Cellular Therapies to $87 From $79, Maintains Neutral Rating
GlobeNewswire
a month ago
Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences
Compare ITCI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ITCI Intra-Cellular Therapies Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.